Literature DB >> 9343160

Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2.

E L Parr1, M B Parr.   

Abstract

We investigated the protective role of antibodies in vaginal secretions of mice that were immune to vaginal challenge with herpes simplex virus type 2 (HSV-2). Unfractionated vaginal immunoglobulins from immune and nonimmune mice and affinity-purified immunoglobulin G (IgG) and secretory IgA (S-IgA) from immune secretions were adjusted to their concentrations in vivo. Wild-type HSV-2 was incubated in the immunoglobulin preparations for 15 min in vitro, followed by inoculation into vaginae of nonimmune mice. HSV-2 was neutralized by unfractionated antibody and purified IgG from immune secretions but not by unfractionated nonimmune antibody or by purified immune S-IgA. The protective effect of IgG in vivo was investigated by passively transferring purified serum IgG from immune and nonimmune donors to nonimmune recipients before vaginal challenge infection. Immune IgG significantly reduced the percentage of vaginal epithelium infected, concentrations of shed virus protein in the vaginal lumen, and illness scores, even though the viral antibody titers in serum and vaginal secretions of recipient mice at the time of challenge were only 29 and 8%, respectively, of those in actively immunized mice. Additionally, removal of vaginal secretions from immune mice 10 min before vaginal challenge with HSV-2 significantly increased the concentration of shed virus protein in the vaginal lumen after challenge. Collectively, the data indicate that IgG antibody in vaginal secretions of immune mice provides early protection against vaginal challenge infection, probably by neutralizing virus in the vaginal lumen. In contrast, S-IgA antibody contributed relatively little to immune protection of the vagina.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343160      PMCID: PMC192266     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

Review 1.  Mucosal immunity and vaccination.

Authors:  J Holmgren
Journal:  FEMS Microbiol Immunol       Date:  1991-12

Review 2.  Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity.

Authors:  M K Slifka; R Ahmed
Journal:  Trends Microbiol       Date:  1996-10       Impact factor: 17.079

3.  Effect of B cell suppression on primary infection and reinfection of mice with herpes simplex virus.

Authors:  A Simmons; A A Nash
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

4.  Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.

Authors:  M R McDermott; L J Brais; M J Evelegh
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

5.  Antibody responses and infertility in mice following oral immunization with attenuated Salmonella typhimurium expressing recombinant murine ZP3.

Authors:  X Zhang; Y H Lou; M Koopman; T Doggett; K S Tung; R Curtiss
Journal:  Biol Reprod       Date:  1997-01       Impact factor: 4.285

6.  Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide.

Authors:  M D Drew; A Estrada-Correa; B J Underdown; M R McDermott
Journal:  J Gen Virol       Date:  1992-09       Impact factor: 3.891

7.  Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes.

Authors:  M R McDermott; P L Brais; G C PLoettsche; M J Evelegh; C H Goldsmith
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

8.  Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.

Authors:  G N Milligan; D I Bernstein
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

9.  Poliovirus hybrids expressing neutralization epitopes from variable domains I and IV of the major outer membrane protein of Chlamydia trachomatis elicit broadly cross-reactive C. trachomatis-neutralizing antibodies.

Authors:  A D Murdin; H Su; M H Klein; H D Caldwell
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

10.  Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2.

Authors:  M Hazama; A Mayumi-Aono; T Miyazaki; S Hinuma; Y Fujisawa
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

View more
  32 in total

1.  Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

Authors:  A M Harandi; B Svennerholm; J Holmgren; K Eriksson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

3.  Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.

Authors:  N Mielcarek; I Nordström; F D Menozzi; C Locht; J Holmgren
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.

Authors:  E L Parr; M B Parr
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

5.  Quantitative analysis of herpes simplex virus type 1-specific memory B cells generated by different routes of infection.

Authors:  Daisy J Vanitha; Hye Mee Joo; Barry T Rouse; Mark Y Sangster
Journal:  Virology       Date:  2006-11-17       Impact factor: 3.616

6.  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination.

Authors:  K Eriksson; M Quiding-Järbrink; J Osek; A Möller; S Björk; J Holmgren; C Czerkinsky
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

7.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.

Authors:  Francois-Xavier Mbopi-Kéou; Laurent Bélec; Julie Dalessio; Jérôme Legoff; Gérard Grésenguet; Philippe Mayaud; David W G Brown; Rhoda Ashley Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

9.  Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice.

Authors:  M B Parr; G R Harriman; E L Parr
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

10.  Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops.

Authors:  Jessica G Cole; Ann E Jerse
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.